RECURRENT FALLOPIAN TUBE CARCINOMA
Clinical trials for RECURRENT FALLOPIAN TUBE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT FALLOPIAN TUBE CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT FALLOPIAN TUBE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for recurrent ovarian cancer in early trial
Disease control OngoingThis early-phase study tests a new drug (berzosertib) added to standard chemotherapy for women with ovarian, peritoneal, or fallopian tube cancer that has returned after initial treatment. The goal is to find the safest dose and see if the combination works better than chemo alon…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:22 UTC
-
Ovarian cancer study tests which chemo combo works best
Disease control OngoingThis study compares two chemotherapy regimens (carboplatin+paclitaxel vs oxaliplatin+capecitabine), with or without the drug bevacizumab, as first treatment for mucinous ovarian or fallopian tube cancer. About 50 participants with newly diagnosed or recurrent disease are enrolled…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:20 UTC
-
New hope for ovarian cancer: drug combo targets resistant tumors
Disease control OngoingThis study tests a drug called adavosertib, given alone or with olaparib, in women with ovarian, fallopian tube, or peritoneal cancer that has returned and stopped responding to PARP inhibitor treatment. The goal is to see if these drugs can shrink tumors or slow their growth. Ab…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:17 UTC
-
New drug combo targets recurrent ovarian and endometrial cancers
Disease control OngoingThis early-phase study tests a combination of two oral and intravenous drugs (niraparib and copanlisib) in people whose endometrial, ovarian, peritoneal, or fallopian tube cancer has returned. The main goal is to find the safest dose and understand side effects. About 31 particip…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:17 UTC
-
New combo aims to outsmart recurrent ovarian cancer
Disease control OngoingThis study tests whether adding an immunotherapy drug (tremelimumab) to a standard targeted therapy (olaparib) can better control recurrent ovarian, fallopian tube, or peritoneal cancer that still responds to platinum chemotherapy. About 61 adults with these cancers will receive …
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:16 UTC
-
New Triple-Drug cocktail shows promise for Tough-to-Treat ovarian and endometrial cancers
Disease control OngoingThis study tests a new combination of three FDA-approved drugs (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the triple therapy shrinks tumors…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: Floor Backes, MD • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New combo therapy targets Hard-to-Treat recurrent cancers
Disease control OngoingThis early-phase trial studies two drug combinations (olaparib plus vistusertib or olaparib plus capivasertib) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The main goal is to find the safest dose and understand side effects. About 15…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New combo therapy aims to extend life in recurrent ovarian cancer
Disease control OngoingThis study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with recurrent ovarian, peritoneal, or fallopian tube cancer live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus bevacizumab, …
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo shows promise
Disease control OngoingThis study tests whether adding a drug called AZD1775 to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has returned and is resistant to platinum-based treatments. About 124 women will be randomly assigned to receive either…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:11 UTC
-
Engineered immune cells take on Hard-to-Treat ovarian cancer
Disease control OngoingThis early-stage trial tests a new treatment for ovarian, fallopian tube, or peritoneal cancer that has returned or not responded to standard therapy. Patients receive their own T cells that have been genetically modified to recognize and attack cancer cells, along with a drug ca…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo shows promise in clinical trial
Disease control OngoingThis study tests whether adding an experimental drug called M6620 to standard chemotherapy (gemcitabine) works better than gemcitabine alone for people with ovarian, peritoneal, or fallopian tube cancer that has returned and no longer responds to platinum-based treatments. About …
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New hope for hard-to-treat ovarian cancer: three-drug showdown
Disease control OngoingThis study compares three different combinations of chemotherapy and targeted drugs in 444 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based chemotherapy. The goal is to find which combination best delays cancer growt…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New drug combo could offer alternative to chemo for recurrent ovarian cancer
Disease control OngoingThis phase 3 study tested whether the targeted drugs olaparib (alone or combined with cediranib) work better than standard platinum-based chemotherapy for women with ovarian, fallopian tube, or primary peritoneal cancer that came back after initial treatment. About 579 women with…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Promising drug cocktail targets Hard-to-Treat ovarian cancers
Disease control OngoingThis study tests a combination of two drugs—veliparib and topotecan—in people with advanced solid tumors or ovarian cancer that has returned after initial treatment. The goal is to find the safest dose and see how well the drugs shrink tumors. About 88 adults are taking part in t…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Measles virus hijacks stem cells to attack returning ovarian cancer
Disease control OngoingThis study tests a new way to treat ovarian cancer that has come back after standard chemotherapy. Doctors take stem cells from fat tissue, infect them with a specially modified measles virus, and inject them into the belly. The stem cells carry the virus directly to cancer cells…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New hope for ovarian cancer: drug combo targets resistant tumors
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The goal is to find the safest dose and see if the combo can shrink tumors or slow their gr…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New drug combo shows promise for Tough-to-Treat ovarian and endometrial cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs, APG-1252 and cobimetinib, in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see if the drugs can shrink or stabilize tumors. About 42 adults with advanced or recurrent cance…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:09 UTC
-
New combo aims to stall ovarian Cancer's return
Disease control OngoingThis study tests whether combining an immunotherapy drug (pembrolizumab) with chemotherapy (carboplatin) can delay cancer progression in people with ovarian, fallopian tube, or primary peritoneal cancer that has returned. Participants have a rising CA-125 blood marker but no visi…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
Heated chemo during surgery shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis early-phase study tests whether giving a dose of heated chemotherapy directly into the abdomen during surgery can help lower the risk of cancer returning in people with advanced ovarian, fallopian tube, uterine, or peritoneal cancer. About 40 participants with stage III or I…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
New drug duo shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study looked at whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that came back or grew during platinum-based chemo. About 582 women took pa…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New drug duo targets Hard-to-Treat brain tumors
Disease control OngoingThis early-phase trial tests a new drug (MLN0128) combined with bevacizumab in people with recurrent glioblastoma (a brain cancer) or other advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and understand side ef…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:50 UTC